Cargando…

Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study

There is need for a brief but comprehensive objective assessment tool to help clinicians evaluate relapse symptoms in patients with multiple sclerosis (MS) and their impact on daily functioning, as well as response to treatment. The 2-part Assessing Relapse in Multiple Sclerosis (ARMS) questionnaire...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrin Ross, Amy, Williamson, Alona, Smrtka, Jennifer, Flemming Tracy, Tracy, Saunders, Carol, Easterling, Constance, Niewoehner, John, Mutschler, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677606/
https://www.ncbi.nlm.nih.gov/pubmed/23766909
http://dx.doi.org/10.1155/2013/470476
_version_ 1782272743611301888
author Perrin Ross, Amy
Williamson, Alona
Smrtka, Jennifer
Flemming Tracy, Tracy
Saunders, Carol
Easterling, Constance
Niewoehner, John
Mutschler, Nicole
author_facet Perrin Ross, Amy
Williamson, Alona
Smrtka, Jennifer
Flemming Tracy, Tracy
Saunders, Carol
Easterling, Constance
Niewoehner, John
Mutschler, Nicole
author_sort Perrin Ross, Amy
collection PubMed
description There is need for a brief but comprehensive objective assessment tool to help clinicians evaluate relapse symptoms in patients with multiple sclerosis (MS) and their impact on daily functioning, as well as response to treatment. The 2-part Assessing Relapse in Multiple Sclerosis (ARMS) questionnaire was developed to achieve these aims. Part 1 consists of 7 questions that evaluate relapse symptoms, impact on activities of daily living (ADL), overall functioning, and response to treatment for previous relapses. Part 2 consists of 7 questions that evaluate treatment response in terms of symptom relief, functioning, and tolerability. The ARMS questionnaire has been evaluated in 103 patients with MS. The most commonly reported relapse symptoms were numbness/tingling (67%), fatigue (58%), and leg/foot weakness (55%). Over half of patients reported that ADL or overall functioning were affected very much (47%) or severely (11%) by relapses. Prescribed treatments for relapses included intravenous and/or oral corticosteroids (87%) and adrenocorticotropic hormone (13%). Nearly half of patients reported that their symptoms were very much (33%) or completely resolved (16%) following treatment. The most commonly reported adverse events were sleep disturbance (45%), mood changes (33%), weight gain (29%), and increased appetite (26%). Systematic assessment of relapses and response to relapse treatment may help clinicians to optimize outcomes for MS patients.
format Online
Article
Text
id pubmed-3677606
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-36776062013-06-13 Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study Perrin Ross, Amy Williamson, Alona Smrtka, Jennifer Flemming Tracy, Tracy Saunders, Carol Easterling, Constance Niewoehner, John Mutschler, Nicole Mult Scler Int Clinical Study There is need for a brief but comprehensive objective assessment tool to help clinicians evaluate relapse symptoms in patients with multiple sclerosis (MS) and their impact on daily functioning, as well as response to treatment. The 2-part Assessing Relapse in Multiple Sclerosis (ARMS) questionnaire was developed to achieve these aims. Part 1 consists of 7 questions that evaluate relapse symptoms, impact on activities of daily living (ADL), overall functioning, and response to treatment for previous relapses. Part 2 consists of 7 questions that evaluate treatment response in terms of symptom relief, functioning, and tolerability. The ARMS questionnaire has been evaluated in 103 patients with MS. The most commonly reported relapse symptoms were numbness/tingling (67%), fatigue (58%), and leg/foot weakness (55%). Over half of patients reported that ADL or overall functioning were affected very much (47%) or severely (11%) by relapses. Prescribed treatments for relapses included intravenous and/or oral corticosteroids (87%) and adrenocorticotropic hormone (13%). Nearly half of patients reported that their symptoms were very much (33%) or completely resolved (16%) following treatment. The most commonly reported adverse events were sleep disturbance (45%), mood changes (33%), weight gain (29%), and increased appetite (26%). Systematic assessment of relapses and response to relapse treatment may help clinicians to optimize outcomes for MS patients. Hindawi Publishing Corporation 2013 2013-05-26 /pmc/articles/PMC3677606/ /pubmed/23766909 http://dx.doi.org/10.1155/2013/470476 Text en Copyright © 2013 Amy Perrin Ross et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Perrin Ross, Amy
Williamson, Alona
Smrtka, Jennifer
Flemming Tracy, Tracy
Saunders, Carol
Easterling, Constance
Niewoehner, John
Mutschler, Nicole
Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study
title Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study
title_full Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study
title_fullStr Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study
title_full_unstemmed Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study
title_short Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study
title_sort assessing relapse in multiple sclerosis questionnaire: results of a pilot study
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677606/
https://www.ncbi.nlm.nih.gov/pubmed/23766909
http://dx.doi.org/10.1155/2013/470476
work_keys_str_mv AT perrinrossamy assessingrelapseinmultiplesclerosisquestionnaireresultsofapilotstudy
AT williamsonalona assessingrelapseinmultiplesclerosisquestionnaireresultsofapilotstudy
AT smrtkajennifer assessingrelapseinmultiplesclerosisquestionnaireresultsofapilotstudy
AT flemmingtracytracy assessingrelapseinmultiplesclerosisquestionnaireresultsofapilotstudy
AT saunderscarol assessingrelapseinmultiplesclerosisquestionnaireresultsofapilotstudy
AT easterlingconstance assessingrelapseinmultiplesclerosisquestionnaireresultsofapilotstudy
AT niewoehnerjohn assessingrelapseinmultiplesclerosisquestionnaireresultsofapilotstudy
AT mutschlernicole assessingrelapseinmultiplesclerosisquestionnaireresultsofapilotstudy